Almirall closes gap in product portfolio through commercialization agreement with MC2

Spanish dermatology company Almirall's purchase of European rights for MC2 Therapeutics-developed drug gives the company a much-needed treatment for patients suffering from mild or moderate psoriasis.

Photo: Almirall / PR

Read this article for free

Register with your E-mail.
No credit card required.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs